Name two other NCBI papers that supported equivalence or superiority of endovascular therapy versus bypass.

Name two other NCBI papers that supported equivalence or superiority of endovascular therapy versus bypass.

• A. L. Uccioli 2018: Treatment of CLI higher morbidity and hospital costs for surgery bypass pts; BASIL multicenter
• B. Nevelle 2009
• C. BASIL multicenter
• D. Uccioli 2019

Answer: (A)

The main idea being tested is evidence on how endovascular therapy compares to bypass for treating critical limb ischemia, specifically studies that show endovascular options are at least as good as, or better than, bypass in terms of outcomes and cost. This answer is the best because it directly cites BASIL multicenter data and a related analysis by Uccioli. The BASIL multicenter trial is a foundational source comparing endovascular revascularization to surgical bypass, with findings that support similar long-term outcomes and highlight scenarios where less invasive endovascular approaches can offer advantages. The Uccioli 2018 paper uses BASIL multicenter data to show higher morbidity and hospital costs associated with surgery bypass, which reinforces the view that endovascular therapy can be superior or at least preferable from a perioperative and economic standpoint. Together, these references provide clear evidence favoring endovascular therapy relative to bypass, aligning with the question’s aim. The other options don’t clearly present this combination of BASIL-based evidence or may not address the endovascular-versus-bypass comparison in the same way.

The main idea being tested is evidence on how endovascular therapy compares to bypass for treating critical limb ischemia, specifically studies that show endovascular options are at least as good as, or better than, bypass in terms of outcomes and cost.

This answer is the best because it directly cites BASIL multicenter data and a related analysis by Uccioli. The BASIL multicenter trial is a foundational source comparing endovascular revascularization to surgical bypass, with findings that support similar long-term outcomes and highlight scenarios where less invasive endovascular approaches can offer advantages. The Uccioli 2018 paper uses BASIL multicenter data to show higher morbidity and hospital costs associated with surgery bypass, which reinforces the view that endovascular therapy can be superior or at least preferable from a perioperative and economic standpoint. Together, these references provide clear evidence favoring endovascular therapy relative to bypass, aligning with the question’s aim.

The other options don’t clearly present this combination of BASIL-based evidence or may not address the endovascular-versus-bypass comparison in the same way.